Stevanato Group S.p.A.

NYSE:STVN

Medical - Instruments & Supplies

Healthcare
$15.36 +3.90%

+$0.67 today

Market cap
$4.20B
Beta
0.78
P/E (TTM)
29.9
EPS (TTM)
$0.52
Dividend yield
0.35%
52W Low $12.89High $28.00

Volume 0.61M

Average 0.52M

STVN Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Stevanato Group S.p.A.NYSE: STVN

Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026

Capital expenditures growth accelerates

Q2 FY2026 capital expenditures of €65.73M (cash outflow) rose 9.1% year over year, ahead of the -38.5% change in trailing-twelve-month capital expenditures. Sequentially, it fell 7.1% from the prior quarter. Over 3 fiscal years it compounded at +1.4% a year.

Context

  • Capital expenditures amounted to 22.2% of revenue in FY2025, down 6.2 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +9.1% holds above the trailing-twelve-month pace of -38.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-€65.73M-7.1% QoQ
Last fiscal yearDec 2025
-€253.35M-19.2% YoY
LTMJun 2026
-€272.65M-38.5% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.1%——
1 year-19.2%——
3-year CAGR+1.4%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

EUR · from the cash flow

Latest · FY2025
(253.35M) EUR
Year-over-year change
+19.2%

Capital Expenditures vs competitors

How STVN compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -38.5% is the 7th highest of 10, against a peer median of -9.4%.
  • Capital expenditures amounts to 22.3% of revenue for STVN, versus a peer median of 1.5%.
STVN Competitors
Capital Expenditures for STVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLCOBausch + Lomb CorporationLTM Jun 2026$318.06M USD-9.4%+25.9%6.0%
ATRAptarGroup, Inc.LTM Jun 2026$273.09M USD-0.6%-5.0%6.9%
STVNStevanato Group S.p.A.LTM Jun 2026€272.65M EUR-38.5%+1.4%22.3%
AVTRAvantor, Inc.LTM Jun 2026$142.3M USD+13.0%-1.2%2.2%
BTSGBrightSpring Health Services, Inc. Common StockLTM Sep 2026$110.33M USD+50.9%+10.8%0.7%
CHEChemed CorporationLTM Jun 2026$66.35M USD+19.8%+3.1%2.6%
MASIMasimo CorporationLTM Apr 2026$23.2M USD-47.9%-29.9%1.5%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$21.52M USD-22.3%+23.5%1.3%
TFXTeleflex IncorporatedLTM Jun 2026$11.81M USD-90.0%+6.3%0.5%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$129K USD-44.2%-11.9%0.0%
NUVLNuvalent, Inc.LTM Mar 2026$0 USD———
Peer median (excluding STVN) —-9.4%+3.1%1.5%

Competitors are the stored peer set for STVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income165.67M187.64M189.55M160.29M134.32M
Depreciation & Amortization56.38M64.82M78.48M80.65M88.57M
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital(41.63M)(117.74M)(102.48M)(17.41M)48.63M
Accounts Receivables(54.77M)(46.42M)(93.86M)(3.83M)855.83K
Inventory(31.2M)(107.37M)(113.59M)12.31M(39.82M)
Accounts Payables44.34M36.05M104.97M(25.89M)87.59M
Other Working Capital00000
Other Non-Cash Items(47.09M)(31.41M)(60.34M)(67.76M)3.27M
Operating Cash Flow133.34M103.31M105.21M155.78M274.79M
Capital Expenditures(113.18M)(243.13M)(441.93M)(313.57M)(253.35M)
Acquisitions (Net)14.81M0(3.59M)(175K)1.79M
Purchases of Investments00000
Sales of Investments773K31K00241.09K
Other Investing Activities(4.32M)(7.95M)15.6M(7.44M)0
Investing Cash Flow(96.43M)(242.95M)(421.22M)(310.21M)(262.15M)
Debt Repayment(120.18M)(31.04M)172.57M27.91M41.38M
Common Stock Issued380.09M00169.77M0
Common Stock Repurchased00000
Dividends Paid(11.2M)(13.5M)(14.29M)(14.46M)(14.16M)
Other Financing Activities6.13M0(250K)0(6.03M)
Financing Cash Flow254.85M(44.54M)158.03M183.22M21.19M
Effect of Forex Changes3.68M1.88M(1.16M)(115K)10.11M
Net Change in Cash295.44M(182.3M)(159.14M)28.67M43.94M
Free Cash Flow20.16M(139.82M)(336.72M)(157.8M)21.44M

Stevanato Group S.p.A.

NYSE:STVN

Intrinsic Alpha fair value

Locked

Current Price

$15.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.